CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $240.3 million in its first quarter.The Cambridge, Massachusetts-based company said it had a loss of $2 per share.The results did not meet Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of $1.93 per share.The RNA interference drug developer posted revenue of $213.3 million in the period, which also did not meet Street forecasts. Eight analysts surveyed by Zacks expected $243.8 million.Alnylam shares have decreased nearly 9% since the beginning of the year. The stock has climbed almost 10% in the last 12 months._____This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY